This research tests a new product for patients who have had a heart attack (AMI, acute myeocardial infarction). This product would help protect and regenerate cells in a heart damaged by AMI.

Rion is a clinical‐phase regenerative medicine company based in Rochester, MN, focused on bringing novel regenerative technologies solving unmet medical needs of the people of Minnesota.

This clinical trial investigates whether adipose-derived (fat tissue-derived) mesenchymal stem cells can be safely administered into the cerebrospinal fluid of patients with traumatic spinal cord injury and what the effects this may have on functional improvement, activities of daily living, and quality of life. If successful, this study may create a viable clinical option for spinal cord injury patients by establishing feasibility and safety data for patients who do not have many treatment options.

The goals of this project are to test the initial safety and feasibility of RECLAIM, a single stage cartilage repair technique using the patient’s own cartilage cells and allogeneic mesenchymal stem cells.  The study will assess patient’s improvement in pain and function following the procedure, while actively monitoring safety and adverse events.

When a baby’s lungs are not adequately developed at birth, severe complications and even death can result. Dr. Ruano brings expertise in a technique that uses a minimally invasive procedure to intervene while the fetus is still in the uterus. He will participate as one investigator in a larger clinical trial to see if this procedure can regenerate the process of lung growth and development before birth.

Year One Progress Report:

Interim report: Patient enrollment continues. Additionally, correlative studies have provided important data on regulatory T cell responses and other markers that give insight to the clinical trial and help strengthen the results.

This grant is in no-cost extension through 2/28/2020.

The overall objective of this proposal is to conduct a multi-site, placebo-controlled Phase IIA clinical trial to obtain clinical data on the safety, efficacy and mechanism of action of intrathecal injection of adipose-derived mesenchymal stem cells as a regenerative therapy for the treatment of the incurable condition, amyotrophic lateral sclerosis.

Read Staff’s most recent interim report here

The goal of this Phase I study is to establish the safety and feasibility of intramyocardial injection of autologous bone marrow derived mononuclear cells (BM-MNC) into the myopathic right ventricle of patients with Ebstein anomaly (EA) at time of elective cardiac surgery.

In no-cost extension to enroll additional patients in study

Read Holst’s most recent NCE Interim Progress Report here